Whitefort Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Whitefort Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.8M	Buy	15,794,261 +863,376	+6%	+$3.79M	18.69%	1
2026 Q1	$67.2M	Buy	14,930,885 +1,587,657	+12%	+$6.94M	19.81%	1
2025 Q4	$64.2M	Hold	13,343,228	–	–	16.41%	1
2025 Q3	$60.6M	Hold	13,343,228	–	–	17.9%	1
2025 Q2	$41.2M	Buy	13,343,228 +35,261	+0.3%	+$117K	15.46%	3
2025 Q1	$46.4M	Buy	13,307,967 +66,051	+0.5%	+$220K	21.85%	1
2024 Q4	$43.3M	Buy	13,241,916 +373,949	+3%	+$1.38M	20.72%	1
2024 Q3	$49.5M	Hold	12,867,967	–	–	22.56%	1
2024 Q2	$39.8M	Buy	12,867,967 +5,815	+0%	+$17.4K	24.51%	1
2024 Q1	$33.2M	Sell	12,862,152 -334,910	-3%	-$867K	20.21%	2
2023 Q4	$33M	Buy	13,197,062 +1,301,585	+11%	+$2.55M	21.03%	2
2023 Q3	$24.1M	Buy	11,895,477 +3,801,556	+47%	+$7.97M	12.66%	3
2023 Q2	$18.6M	Buy	8,093,921 +593,895	+8%	+$1.55M	17.48%	2
2023 Q1	$22.7M	Buy	7,500,026 +3,649,257	+95%	+$10.3M	21.12%	2
2022 Q4	$8.97M	Buy	+3,850,769	New	+$9.21M	6.97%	6

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Whitefort Capital Management's ABUS Position: Q2 2026 in Review

Whitefort Capital Management increased its Arbutus Biopharma (ABUS) stake by 5.8% in Q2 2026, buying an estimated $3.79M and bringing the position to 15,794,261 shares worth $75.8M. The position accounts for 18.69% of the portfolio, ranked #1.

Whitefort Capital Management first reported a position in ABUS in Q4 2022 and has held it in 15 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Whitefort Capital Management held 15,794,261 shares of Arbutus Biopharma worth $75.8M as of Q2 2026.
Whitefort Capital Management bought 863,376 Arbutus Biopharma shares in Q2 2026, an estimated $3.79M.
Arbutus Biopharma made up 18.69% of Whitefort Capital Management's portfolio in Q2 2026, its #1 holding.
Whitefort Capital Management first reported a position in Arbutus Biopharma in Q4 2022 and has held it in 15 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Whitefort Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.